Glucagon-like peptide-1 (GLP-1) receptor agonists may reduce hospitalizations, amputations, and deaths among people with peripheral artery disease (PAD) and type 2 diabetes compared with metformin, a new study suggests.
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | GLP-1s may improve outcomes in patients with PAD, diabetes | 5 | 7 | 08-07-2026 |
| 2 | Weight loss drugs may literally be saving people's arms and legs | 5 | 7 | 06-07-2026 |
| 3 | New GLP-1 diabetes pill delivers major weight loss and blood sugar control | 0 | 6.91 | 15-06-2026 |
| 4 | Popular GLP-1 weight-loss drugs like Ozempic slash heart attack and stroke risk | 0 | 9.67 | 21-05-2026 |
| 5 | GLP-1 Agonists May Help People With Diabetes and Long COVID | 0 | 10.36 | 09-07-2026 |
| 6 | GLP-1s for diabetes may increase risk for psoriatic disease | 0 | 8.45 | 28-07-2026 |
| 7 | Bofanglutide linked to meaningful reductions in HbA1c in adults with T2DM | 5 | 7 | 02-07-2026 |
| 8 | GLP-1s may lower risk for death, heart events among people with hidradenitis suppurativa | 5 | 7 | 08-07-2026 |
| 9 | GLP-1 drugs could become personalized for individuals, study says | 0 | 14.17 | 01-08-2026 |